Townsend & Associates’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.76M Sell
45,898
-547
-1% -$31.4K 0.24% 52
2026
Q1
$2.73M Sell
46,445
-322
-0.7% -$18.8K 0.24% 51
2025
Q4
$2.65M Sell
46,767
-1,405
-3% -$67.6K 0.24% 50
2025
Q3
$2.1M Buy
48,172
+39
+0.1% +$1.82K 0.2% 53
2025
Q2
$2.33M Buy
48,133
+791
+2% +$38.8K 0.23% 49
2025
Q1
$2.32M Buy
47,342
+2,817
+6% +$164K 0.24% 48
2024
Q4
$2.54M Sell
44,525
-124
-0.3% -$6.93K 0.26% 49
2024
Q3
$2.37M Buy
44,649
+1,051
+2% +$49.3K 0.24% 49
2024
Q2
$2.2M Buy
43,598
+472
+1% +$21.1K 0.24% 48
2024
Q1
$2.11M Buy
43,126
+3,070
+8% +$156K 0.25% 48
2023
Q4
$2.01M Sell
40,056
-2,154
-5% -$113K 0.25% 48
2023
Q3
$2.15M Sell
42,210
-1,640
-4% -$100K 0.45% 46
2023
Q2
$2.8M Sell
43,850
-252
-0.6% -$16.9K 0.72% 45
2023
Q1
$2.94M Buy
44,102
+17,422
+65% +$1.23M 1.18% 30
2022
Q4
$1.95M Buy
26,680
+5,364
+25% +$404K 0.97% 39
2022
Q3
$1.71M Buy
21,316
+3,934
+23% +$285K 0.79% 45
2022
Q2
$1.31M Buy
+17,382
New +$1.32M 0.61% 58

Other funds holding BMY

Townsend & Associates's BMY Position: Q2 2026 in Review

Townsend & Associates reduced its Bristol-Myers Squibb (BMY) stake by 1.2% in Q2 2026, selling an estimated $31.4K and leaving 45,898 shares worth $2.76M. The position accounts for 0.24% of the portfolio, ranked #52.

Townsend & Associates first reported a position in BMY in Q2 2022 and has held it in 17 quarters since. The position peaked at $2.94M in Q1 2023. 878 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Townsend & Associates held 45,898 shares of Bristol-Myers Squibb worth $2.76M as of Q2 2026.
  • Townsend & Associates sold 547 Bristol-Myers Squibb shares in Q2 2026, an estimated $31.4K.
  • Bristol-Myers Squibb made up 0.24% of Townsend & Associates's portfolio in Q2 2026, its #52 holding.
  • Townsend & Associates first reported a position in Bristol-Myers Squibb in Q2 2022 and has held it in 17 quarters since.
  • Townsend & Associates's Bristol-Myers Squibb position peaked at $2.94M in Q1 2023.
  • 878 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Townsend & Associates's 13F filing for Q2 2026, filed 22 Jul 2026.